Adaptive Biotechnologies (ADPT) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Adaptive Biotechnologies in October 2026.
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Adaptive Biotechnologies (ADPT) Stock Forecast
Analyst price target, next 12 months
$22.45
-10.9% vs today's $25.19
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Adaptive Biotechnologies have a consensus 12-month target of $22.45, below the current price of $25.19.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Adaptive Biotechnologies' stock with a target price of $22.45, indicating potential growth.
Financial Health
Adaptive Biotechnologies is generating strong revenue and cash flow, with high profitability margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
